Kamada Stock Sees Q3 Earnings Estimate Cut at Sidoti

Key Points

• Sidoti lowered Kamada’s Q3 2028 EPS estimate to $0.13 from $0.15, while the full-year consensus estimate stands at $0.48 per share.
• Kamada’s latest quarterly results exceeded expectations, with EPS of $0.16 versus the $0.11 consensus and revenue of $54.92 million versus $50.84 million expected.
• Analysts maintain a favorable outlook, with a consensus “Buy” rating and average price target of $13.50; however, Kamada recently reduced its annual dividend to $0.17 from $0.25 per share.

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Equities research analysts at Sidoti decreased their Q3 2028 earnings per share (EPS) estimates for Kamada in a research report issued to clients and investors on Friday, September 25th. Sidoti analyst J. Sidoti now forecasts that the biotechnology company will earn $0.13 per share for the quarter, down from their prior forecast of $0.15. The consensus estimate for Kamada's current full-year earnings is $0.48 per share.

Kamada (NASDAQ:KMDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.05. The firm had revenue of $54.92 million for the quarter, compared to the consensus estimate of $50.84 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%.

KMDA has been the subject of a number of other research reports. UBS Group reissued a "buy" rating and issued a $15.00 price objective on shares of Kamada in a report on Friday, September 18th. Benchmark reaffirmed a "buy" rating on shares of Kamada in a research note on Tuesday, July 21st. Weiss Ratings restated a "buy (b-)" rating on shares of Kamada in a report on Tuesday, September 22nd. William Blair set a $15.00 price target on shares of Kamada in a research report on Tuesday, July 21st. Finally, Wall Street Zen upgraded Kamada from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $13.50.

Kamada Stock Down 3.1%

Shares of KMDA opened at $8.20 on Friday. Kamada has a 52-week low of $6.50 and a 52-week high of $9.35. The company has a market capitalization of $471.58 million, a PE ratio of 21.58, a price-to-earnings-growth ratio of 0.71 and a beta of 0.89. The stock has a fifty day simple moving average of $7.98 and a two-hundred day simple moving average of $7.88.

Institutional Investors Weigh In On Kamada

A hedge fund recently raised its position in Kamada stock. Aristides Capital LLC boosted its position in Kamada Ltd. (NASDAQ:KMDA - Free Report) by 4.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,491 shares of the biotechnology company's stock after acquiring an additional 1,476 shares during the quarter. Aristides Capital LLC owned 0.06% of Kamada worth $288,000 at the end of the most recent quarter. 20.38% of the stock is currently owned by institutional investors.

Kamada Cuts Dividend

The company also recently declared an annual dividend, which was paid on Thursday, September 17th. Shareholders of record on Thursday, August 27th were paid a dividend of $0.17 per share. This represents a yield of 206.0%. This is a negative change from Kamada's previous annual dividend of $0.25. The ex-dividend date was Thursday, August 27th. Kamada's payout ratio is currently 34.21%.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company focused on the development, manufacture and commercialization of plasma-derived and specialty pharmaceutical products. The company's portfolio is aimed primarily at treating rare diseases and other conditions requiring replacement or immune-modulating therapies.

Kamada's principal product is GLASSIA, an intravenous alpha-1 proteinase inhibitor used as augmentation therapy in adults with alpha-1 antitrypsin deficiency, a rare genetic disorder that can cause progressive lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.